KIRBY JT, BIEDENBACH DJ, JONES RN; THE SENTRY PARTICIPANTS GROUP; Interscience Conference on Antimicrobial Agents and Chemotherapy (41st : 2001 : Chicago, Ill.).

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2001 Dec 16-19; 41: abstract no. C2-72.

The JONES Group/JMI Laboratories, North Liberty, IA

BACKGROUND: Multi-resistant (R) PSA isolated from blood stream (BSI), respiratory tract (RTI), skin and soft tissue and urinary tract infections (UTI) has subsequently increased morbidity and mortality rates worldwide. The SENTRY Program has gathered global data on pseudomonal isolates for over 4 years to determine prevailing R trends for 8 key anti-PSA drugs. METHODS: SENTRY participants from four regions (centers); NA (44), LA (14), EU (30) and AP (18) collected 9,109 PSA isolates that were tested by reference NCCLS methods against 28 antimicrobials including beta-lactams +/- inhibitor, fluoroquinolones (FQ) and aminoglycosides. RESULTS: Overall spectrum rank order against PSA was: meropenem > piperacillin/tazobactam > imipenem > cefepime (CPM) > ceftazidime (CAZ). Rank order of % S by infection site showed BSI > RTI > UTI with beta-lactam R greatest among RTI strains and FQ-R greatest among UTI isolates. FQ activity ciprofloxacin (CIP; MIC[50], levofloxacin (MIC[50], 0.5-1 microg/ml) but spectrum difference was only 2.5%. PSA showed > S to CPM compared to CAZ against BSI (84% vs 82%) and RTI (77% vs. 75%) in all regions. Regional FQ % S ranked AP (84%) > NA (74%) > EU (68%) > LA (54%). A trend towards decreased S over time in AP (-15%) and NA (-6%) was demonstrataed only for FQs. A decline in S over time for all monitored drugs was found for LA (-6 to -13%) and EU (-6 to -14%) with a greater drop in tested FQ activity. CONCLUSIONS: Extreme variations have emerged in the S patterns of PSA including: inter-regional differences (NA and AP most S); escalating R to FQs (all regions); and declining S to all anti-pseudomonal classes (EU and LA). Continued monitoring of R, local interventions (infection and formulary controls) and new drug development appear essential.

Publication Types:

• Meeting Abstracts

Keywords:

• Aminoglycosides
• Anti-Bacterial Agents
• Anti-Infective Agents
• Asia
• Ceftazidime
• Cephalosporins
• Ciprofloxacin
• Europe
• Fluoroquinolones
• Latex Fixation Tests
• Latin America
• Microbial Sensitivity Tests
• North America
• Ofloxacin
• Urinary Tract Infections
• beta-Lactams
• cefepime

Other ID:

• GWAIDS0030925

UI: 102270562

From Meeting Abstracts